RT Book, Section
A1 Westin, Jason R.
A1 Konoplev, Sergej N.
A1 Fayad, Luis E.
A1 Medeiros, L. Jeffrey
A2 Kantarjian, Hagop M.
A2 Wolff, Robert A.
SR Print(0)
ID 1126740581
T1 Aggressive B-Cell Lymphomas
T2 The MD Anderson Manual of Medical Oncology, 3e
YR 2016
FD 2016
PB McGraw-Hill Medical
PP New York, NY
SN 9780071847940
LK hemonc.mhmedical.com/content.aspx?aid=1126740581
RD 2024/04/19
AB It  is  clinically  useful  to  divide  non-Hodgkin  lymphomas  (NHL)  into  indolent  and  aggressive  based  on  their  clinical  behavior  (1).  Patients  with  indolent  NHL  typically  have  a  survival  of  many  years,  even  if  untreated,  but  paradoxically  are  usually  incurable.  Patients  with  aggressive  NHL  have  a  survival  time  measured  in  weeks  to  months  if  untreated  yet  are  usually  chemosensitive  and  frequently  curable.  In  this  chapter,  we  focus  on  the  clinical  characteristics,  pathology,  and  treatment  of  aggressive  NHL.